The Role of DHA in PSD ‐95 Regulation and Postsynaptic Organization: Implications for Synaptic Function and Neurological Disorders
Journal of Neurochemistry · 2026-11 · 170 (11)
DOI: 10.1111/jnc.70571 ↗Abstract
ABSTRACT Docosahexaenoic acid (DHA), a long‐chain omega‐3 fatty acid, plays a critical role in synaptic function by regulating membrane biophysical properties, neurotransmitter dynamics, and synaptic protein organization; as such, its therapeutic potential for synaptic disorders is an area of considerable research. Among DHA's effects on synapses is its modulation of postsynaptic density protein‐95 (PSD‐95), a key scaffolding protein essential for synaptic stability and plasticity. This review integrates current evidence linking DHA to changes in PSD‐95 expression, synaptic localization, and interactions with glutamate receptors. Specifically, DHA incorporation into neuronal membranes alters lipid packing and membrane microdomain organization, which can influence receptor mobility and clustering. In parallel, DHA also engages intracellular signaling pathways, including protein kinase B (Akt)‐ and cAMP response element‐binding protein (CREB)‐associated signaling, which may contribute to PSD‐95 synthesis, synaptic retention, and postsynaptic stabilization. Bioactive DHA metabolites, such as neuroprotectin D1 (NPD1) and N‐docosahexaenoyl ethanolamide (DHEA; synaptamide), further influence synaptic function via receptor‐mediated signaling at nanomolar concentrations. DHA deficiency disrupts synaptic architecture, impairing long‐term potentiation (LTP) and cognitive function, while DHA repletion following deficiency can restore PSD‐95 levels and selected measures of synaptic function. From a clinical perspective, DHA has shown potential to mitigate synaptic and behavioral deficits in neurodevelopmental disorders such as autism spectrum disorder (ASD) and Fragile X syndrome (FXS) and preserve synaptic integrity in neurodegenerative diseases, including Alzheimer's and Huntington's. However, clinical trials reveal variable outcomes, influenced by factors such as apolipoprotein E (APOE) genotype, dosing regimen, and baseline DHA status. Continued efforts to optimize bioavailability, incorporate genotype‐stratified designs, and evaluate DHA metabolites are essential to advancing its translation from a nutritional supplement to a targeted neuromodulatory therapy for disorders characterized by postsynaptic dysfunction. image
EUVIMED